Frequently Asked Questions
The market is segmented based on Global Gemcitabine HCl Market, By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer, Biliary Tract Cancer, Others), Route of Administration (Intravenous), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
.
The Global Gemcitabine Hcl Market size was valued at USD 612.00 USD Million in 2021.
The Global Gemcitabine Hcl Market is projected to grow at a CAGR of 7% during the forecast period of 2022 to 2029.
The major players operating in the market include Pfizer , F. Hoffmann, La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. , Hikma Pharmaceuticals PLC, Novartis AG, Shanghai Fosun Pharmaceutical Co., Teva Pharmaceutical Industries , HEYER Medical AG, Biometrix, Smiths Medical.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
